REHOVOT, Israel, June 3, 2014 (GLOBE NEWSWIRE) -- Foamix, a clinical-stage, specialty pharmaceutical company today announced a collaboration agreement with the National Eye Institute (NEI), one of the National Institutes of Health, to develop treatments for geographic atrophy (GA). The focus of the collaboration is the development of an effective therapy for GA using Foamix's stable patented topical OilGel® formulation containing minocycline, an antibiotic in the tetracycline family that also has anti-inflammatory, anti-oxidant, anti-apoptotic and neuro-protective properties.
Help employers find you! Check out all the jobs and post your resume.
